Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib Open-label, Multicenter, Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Summary

The purpose of this phase Ib, open label, multi-center, clinical study is to evaluate the safety and efficacy of autologous claudin 18.2 chimeric antigen receptor T-cell Therapy (CAR-T) (CT041) in patients with advanced gastric or pancreatic adenocarcinoma.

General Information

NCT#: NCT04404595
Study ID: CT041-ST-02
Trial Phase: Phase I

Trial Sponsor: Carsgen Therapeutics
Therapies Used in This Trial: CT041

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search